Skip to main content
Top
Published in: Drugs 6/2001

01-05-2001 | Review Article

Fluoroquinolones

Place in Ocular Therapy

Authors: Amy Smith, Philippa M. Pennefather, Dr Stephen B. Kaye, Colin A. Hart

Published in: Drugs | Issue 6/2001

Login to get access

Abstract

The fluoroquinolones have become widely used antibacterial agents in the treatment of ocular infections, with topical, intravitreal and systemic routes of administration being used. In general, fluoroquinolones (such as ciprofloxacin, ofloxacin, lomefloxacin and norfloxacin) have good activity against Gram-negative and Gram-positive bacteria. Therapeutic concentrations are achieved in the cornea after topical administration so that the fluoroqinolones have largely replaced combination therapy for the treatment of bacterial keratitis. However, a second line agent is needed when resistance is likely, such as in disease caused by streptococcal species. Reversal of resistance to quinolones may not occur with withdrawal of the antibacterial. This stresses the importance of prudent prescribing to reduce the occurrence of resistance to quinolones.
When used in therapeutic topical dosages, corneal toxicity does not occur. Similarly, retinal toxicity is not seen when fluoroquinolones are used at therapeutic dosages, systemically or topically. Corneal precipitation occurs, particularly with ciprofloxacin and to a lesser extent norfloxacin, but does not appear to interfere with healing.
In the treatment of endophthalmitis there is reasonable penetration of systemic fluoroquinolones into the vitreous but sufficiently high concentrations to reach the minimum inhibitory concentration for 90% of isolates ( MIC90 ) of all important micro-organisms may not be guaranteed. Systemic administration may be useful for prophylaxis after ocular trauma.
Literature
1.
go back to reference Norris S, Mandell GL. The quinolones: history and overview. Andriole VT, editor. Academic Press Ltd: London. 1988: 1–22 Norris S, Mandell GL. The quinolones: history and overview. Andriole VT, editor. Academic Press Ltd: London. 1988: 1–22
2.
go back to reference Stevens SX, Fouraker BD, Jensen HG. Intraocular safety of ciprofloxacin. Arch Ophthalmol 1991; 109: 1737–43PubMedCrossRef Stevens SX, Fouraker BD, Jensen HG. Intraocular safety of ciprofloxacin. Arch Ophthalmol 1991; 109: 1737–43PubMedCrossRef
3.
go back to reference Ligtovoet EEJ, Wickerhoff-Minoggio T. In vitro activity of penfloxacin compared with six other quinolones. J Antimicrob Chemother 1985; 16: 485–90CrossRef Ligtovoet EEJ, Wickerhoff-Minoggio T. In vitro activity of penfloxacin compared with six other quinolones. J Antimicrob Chemother 1985; 16: 485–90CrossRef
4.
go back to reference Vila J, Ruiz J, Goni P, et al. Detection of mutations in parC in quinolone-resistant clinical isolates of escherichia coli. Antimicrob Agents Chemother 1996; 40(2): 491–3PubMed Vila J, Ruiz J, Goni P, et al. Detection of mutations in parC in quinolone-resistant clinical isolates of escherichia coli. Antimicrob Agents Chemother 1996; 40(2): 491–3PubMed
5.
go back to reference Pan XS, Fisher ML. Targeting of DNA gyrase in streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase iv by quinolones. Antimicrob Agents Chemother 1997; 41(2): 471–4PubMed Pan XS, Fisher ML. Targeting of DNA gyrase in streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase iv by quinolones. Antimicrob Agents Chemother 1997; 41(2): 471–4PubMed
6.
go back to reference Takenouchi T, Tabata F, Iwata Y, et al. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of staph aureus. Antimicrob Agents Chemother 1996; 40(8): 1835–42PubMed Takenouchi T, Tabata F, Iwata Y, et al. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of staph aureus. Antimicrob Agents Chemother 1996; 40(8): 1835–42PubMed
7.
go back to reference Pan X-S, Ambler J, Mehtar S et al. Involvement of Topoisomerase iv and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40(10): 2321–6PubMed Pan X-S, Ambler J, Mehtar S et al. Involvement of Topoisomerase iv and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40(10): 2321–6PubMed
8.
go back to reference Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999; 106(7): 1313–8PubMedCrossRef Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999; 106(7): 1313–8PubMedCrossRef
9.
go back to reference Kaatz GW, Seo S, Ruble CA. Efflux-mediated fluoroquinolone resistance in staphylococcus aureus. Antimicrob Agents Chemother 1993; 37(5): 1086–94PubMedCrossRef Kaatz GW, Seo S, Ruble CA. Efflux-mediated fluoroquinolone resistance in staphylococcus aureus. Antimicrob Agents Chemother 1993; 37(5): 1086–94PubMedCrossRef
10.
go back to reference Tanaka M, Onodera Y, Uchida Y,et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from staphylococcus aureus. Antimicrob Agents Chemother 1997; 41(11): 2362–6PubMed Tanaka M, Onodera Y, Uchida Y,et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from staphylococcus aureus. Antimicrob Agents Chemother 1997; 41(11): 2362–6PubMed
11.
go back to reference Jones ME, Boenink NM, Verhoef J, et al. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment. J Antimicrob Chemother 2000; 45: 353–6PubMedCrossRef Jones ME, Boenink NM, Verhoef J, et al. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment. J Antimicrob Chemother 2000; 45: 353–6PubMedCrossRef
12.
13.
go back to reference Fiscella RG, Nguyen TKP, Cwik MJ et al. Aqueous and Vitreous Penetration of Levofloxacin after Oral Administration. Ophthalmology 1999; 106(12): 2286–90PubMedCrossRef Fiscella RG, Nguyen TKP, Cwik MJ et al. Aqueous and Vitreous Penetration of Levofloxacin after Oral Administration. Ophthalmology 1999; 106(12): 2286–90PubMedCrossRef
14.
go back to reference Smith MA, Alperstein P, France K, et al. Susceptibility testing of propionibacterium acnes comparing agar dilution with E test. J Clin Microbiol 1996; 34(4): 1024–6PubMed Smith MA, Alperstein P, France K, et al. Susceptibility testing of propionibacterium acnes comparing agar dilution with E test. J Clin Microbiol 1996; 34(4): 1024–6PubMed
15.
go back to reference Prosser BLT, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates. Diagn Microbiol Infect Dis 1995; 21: 33–45PubMedCrossRef Prosser BLT, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates. Diagn Microbiol Infect Dis 1995; 21: 33–45PubMedCrossRef
16.
go back to reference Bower K, Kowalski R, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol 1996; 121:(6)712–5PubMed Bower K, Kowalski R, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol 1996; 121:(6)712–5PubMed
17.
go back to reference Jensen HG, Felix C and the In Vitro Antibiotic Testing Group. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Cornea 1998; 17(1): 79–87PubMedCrossRef Jensen HG, Felix C and the In Vitro Antibiotic Testing Group. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Cornea 1998; 17(1): 79–87PubMedCrossRef
18.
go back to reference Everett SL, Kowalski RP, Karenchak LM, et al. An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 1995; 14(4): 382–7PubMedCrossRef Everett SL, Kowalski RP, Karenchak LM, et al. An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 1995; 14(4): 382–7PubMedCrossRef
19.
go back to reference Neu H. Microbiological aspects of fluoroquinolones. Am J Ophthalmol 112: 15S–24S Neu H. Microbiological aspects of fluoroquinolones. Am J Ophthalmol 112: 15S–24S
20.
go back to reference Zhao BY, Pine R, Domagala J, et al. Fluoroqinolone action against clinical isolates of mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999; 43: 661–6PubMed Zhao BY, Pine R, Domagala J, et al. Fluoroqinolone action against clinical isolates of mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999; 43: 661–6PubMed
21.
go back to reference Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213–21PubMedCrossRef Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213–21PubMedCrossRef
22.
go back to reference Just PM. Overview of the fluoroquinolone antibiotics. Pharmacology 1993; 13: S4–17 Just PM. Overview of the fluoroquinolone antibiotics. Pharmacology 1993; 13: S4–17
23.
go back to reference Von Keyserlingk J, Beck R, Fischer U, et al. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humour of patients by different topical application modes. Eur J Clin Pharmacol 1997; 53: 251–5CrossRef Von Keyserlingk J, Beck R, Fischer U, et al. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humour of patients by different topical application modes. Eur J Clin Pharmacol 1997; 53: 251–5CrossRef
24.
go back to reference Green LC, Callegan MC, Engel LS. Pharmacokinetics of topically applied ciprofloxacin in rabbit tears. Jpn J Ophthalmol 1996; 40: 123–6PubMed Green LC, Callegan MC, Engel LS. Pharmacokinetics of topically applied ciprofloxacin in rabbit tears. Jpn J Ophthalmol 1996; 40: 123–6PubMed
25.
go back to reference Borrman L, Tang-Liu DD, Kann J, et al. Ofloxacin in human serum, urine, and tear film after topical application. Cornea 1992; 11: 226–30 Borrman L, Tang-Liu DD, Kann J, et al. Ofloxacin in human serum, urine, and tear film after topical application. Cornea 1992; 11: 226–30
26.
go back to reference Diamond JP, White L, Leeming JP, et al. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthamol 1995; 79: 606–9CrossRef Diamond JP, White L, Leeming JP, et al. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthamol 1995; 79: 606–9CrossRef
27.
go back to reference Donnenfeld ED, Perry HD, Snyder RW et al. Intracorneal, aqueous humor and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997; 115: 173–6PubMedCrossRef Donnenfeld ED, Perry HD, Snyder RW et al. Intracorneal, aqueous humor and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol 1997; 115: 173–6PubMedCrossRef
28.
go back to reference Grayson G, Flowers C, Nassaralla B, et al. Aqueous penetration of 0.3% ciprofloxacin and 0.3% ofloxacin after topical application and a microbial analysis of pre-treatment conjunctiva and post-treatment aqueous humor. Invest Ophthalmol Vis Sci 1995; 36: S160 Grayson G, Flowers C, Nassaralla B, et al. Aqueous penetration of 0.3% ciprofloxacin and 0.3% ofloxacin after topical application and a microbial analysis of pre-treatment conjunctiva and post-treatment aqueous humor. Invest Ophthalmol Vis Sci 1995; 36: S160
29.
go back to reference Bouchard CS, King KK, Holmes JM. The kinetics of anterior chamber ofloxacin penetration. Cornea 1996; 15: 72–5PubMedCrossRef Bouchard CS, King KK, Holmes JM. The kinetics of anterior chamber ofloxacin penetration. Cornea 1996; 15: 72–5PubMedCrossRef
30.
go back to reference McDermott ML, Tran TD, Cowden JW et al. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology 1992; 100: 197–200 McDermott ML, Tran TD, Cowden JW et al. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology 1992; 100: 197–200
31.
go back to reference Reidy JJ, Hobden JA, Hill JM, et al. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea 1991; 10: 25–8PubMed Reidy JJ, Hobden JA, Hill JM, et al. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea 1991; 10: 25–8PubMed
32.
go back to reference Price FW, Whiston WE, Collins KS, et al. Corneal tissue levels of topically applied ciprofloxacin. Cornea 1995; 14: 152–6PubMedCrossRef Price FW, Whiston WE, Collins KS, et al. Corneal tissue levels of topically applied ciprofloxacin. Cornea 1995; 14: 152–6PubMedCrossRef
33.
go back to reference O’Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995; 113: 1257–65PubMedCrossRef O’Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995; 113: 1257–65PubMedCrossRef
34.
go back to reference Pamel GJ, Perl T. Collagen shield delivery of ciprofloxacin in uninflamed eyes. Invest Ophthalmol Vis Sci 1993; S769- Pamel GJ, Perl T. Collagen shield delivery of ciprofloxacin in uninflamed eyes. Invest Ophthalmol Vis Sci 1993; S769-
35.
go back to reference Donnenfeld ED, Schrier A, Perry HD, et al. Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor. Ophthalmology 1994; 101: 902–5PubMed Donnenfeld ED, Schrier A, Perry HD, et al. Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor. Ophthalmology 1994; 101: 902–5PubMed
36.
go back to reference Kowalski RP, Karenchak LM, Gordon YJ. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea 1998; 17: 282–7PubMedCrossRef Kowalski RP, Karenchak LM, Gordon YJ. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea 1998; 17: 282–7PubMedCrossRef
37.
go back to reference Ellner PD, Neu HC. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 1981; 246: 1575–208PubMedCrossRef Ellner PD, Neu HC. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 1981; 246: 1575–208PubMedCrossRef
38.
go back to reference Osato MS. Effect of two balanced salt solutions on the bioavailability of ofloxacin and ciprofloxacin. Adv In Ther 1999; 16(5): 200–9 Osato MS. Effect of two balanced salt solutions on the bioavailability of ofloxacin and ciprofloxacin. Adv In Ther 1999; 16(5): 200–9
39.
go back to reference Agius-Fernandez A, Patterson A, Fsadni M, et al. Topical lomefloxacin versus topical chloramphenicol in the treatment of acute bacterial conjunctivitis. Clin Drug Invest 1998; 15(4): 263–9CrossRef Agius-Fernandez A, Patterson A, Fsadni M, et al. Topical lomefloxacin versus topical chloramphenicol in the treatment of acute bacterial conjunctivitis. Clin Drug Invest 1998; 15(4): 263–9CrossRef
40.
go back to reference Friedlander MH. Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infection. CLAO Journal 1998; 24(1): 49–51 Friedlander MH. Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infection. CLAO Journal 1998; 24(1): 49–51
41.
42.
go back to reference Leibowitz H. Clinical evaluation of ciprofloxacin 0.3%: opthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991; 112: 29S–33SPubMed Leibowitz H. Clinical evaluation of ciprofloxacin 0.3%: opthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991; 112: 29S–33SPubMed
43.
go back to reference Barry AL, Jones RN. In vitro activity of ciprofloxacin against gram-positive cocci. Am J Med 1987; 82: 27–32PubMed Barry AL, Jones RN. In vitro activity of ciprofloxacin against gram-positive cocci. Am J Med 1987; 82: 27–32PubMed
44.
go back to reference Hofman J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481–6CrossRef Hofman J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481–6CrossRef
45.
go back to reference Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% Ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis: the Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol 1993; 111: 1210–8PubMedCrossRef Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% Ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis: the Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol 1993; 111: 1210–8PubMedCrossRef
46.
go back to reference Maffet M, O’Day DM. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol 1993; 115: 545–6 Maffet M, O’Day DM. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol 1993; 115: 545–6
47.
go back to reference Snyder ME, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol 1992; 114: 336–9PubMed Snyder ME, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol 1992; 114: 336–9PubMed
48.
go back to reference Castillo A, Castillo JMB, Toledano N, et al. Deposits of topical norfloxacin in the treatment of bacterial keratitis. Cornea 1997; 16: 420–3PubMedCrossRef Castillo A, Castillo JMB, Toledano N, et al. Deposits of topical norfloxacin in the treatment of bacterial keratitis. Cornea 1997; 16: 420–3PubMedCrossRef
49.
go back to reference Gangopadhyay N, Daniell M, Weih L, et al. Fluoroquinolones and fortified antibiotics for treating bacterial corneal ulcers. BJO 2000; 84: 378–84CrossRef Gangopadhyay N, Daniell M, Weih L, et al. Fluoroquinolones and fortified antibiotics for treating bacterial corneal ulcers. BJO 2000; 84: 378–84CrossRef
50.
go back to reference Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles and preservatives on the corneal epithelium: a scanning electron microscopic study. Invest Ophthalmol 1976; 15: 246–9PubMed Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles and preservatives on the corneal epithelium: a scanning electron microscopic study. Invest Ophthalmol 1976; 15: 246–9PubMed
51.
go back to reference Lin CP, Boehnke M. Effect of fortified antibiotic solutions on corneal epithelial wound healing. Cornea 2000; 19: 204–6PubMedCrossRef Lin CP, Boehnke M. Effect of fortified antibiotic solutions on corneal epithelial wound healing. Cornea 2000; 19: 204–6PubMedCrossRef
52.
go back to reference Burnstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980; 25(1): 15–30CrossRef Burnstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980; 25(1): 15–30CrossRef
53.
go back to reference Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 1996; 103: 1854–63PubMed Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 1996; 103: 1854–63PubMed
54.
go back to reference Baum JL. Treatment of bacterial ulcers of the cornea in the rabbit: a comparison of administration by eye drops and subconjunctival injections. Trans Am Ophthalmol Soc 1982; 80: 369–90PubMed Baum JL. Treatment of bacterial ulcers of the cornea in the rabbit: a comparison of administration by eye drops and subconjunctival injections. Trans Am Ophthalmol Soc 1982; 80: 369–90PubMed
55.
go back to reference Rolando M, Brezzo V, Campagna P, et al. Toxic effects of antimicrobials on the ocular surface of healthy volunteers. Chibret Int J Ophthalmol 1991; 8: 46–50 Rolando M, Brezzo V, Campagna P, et al. Toxic effects of antimicrobials on the ocular surface of healthy volunteers. Chibret Int J Ophthalmol 1991; 8: 46–50
56.
go back to reference Konishi M, Yamada M, Mashima Y. Corneal ulcer associated with deposits of norfloxacin. Am J Ophthalmol 1998; 125(2); 258–60PubMedCrossRef Konishi M, Yamada M, Mashima Y. Corneal ulcer associated with deposits of norfloxacin. Am J Ophthalmol 1998; 125(2); 258–60PubMedCrossRef
57.
go back to reference Petroutsos G, Guimaraes R, Pouliquen Y. The effect of concentrated antibiotics on the rabbit’s corneal epithelium. Int Ophthalmol 1984; 7: 65–9PubMedCrossRef Petroutsos G, Guimaraes R, Pouliquen Y. The effect of concentrated antibiotics on the rabbit’s corneal epithelium. Int Ophthalmol 1984; 7: 65–9PubMedCrossRef
58.
go back to reference Nakamura M, Nishida T, Mishima H, et al. Effects of antimicrobials on corneal epithelial migration. Curr Eye Res 1993; 12: 733–40PubMedCrossRef Nakamura M, Nishida T, Mishima H, et al. Effects of antimicrobials on corneal epithelial migration. Curr Eye Res 1993; 12: 733–40PubMedCrossRef
59.
go back to reference Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28: 581–6PubMedCrossRef Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28: 581–6PubMedCrossRef
60.
go back to reference Kang F, Serdarevic ON, Kuang K, et al. Effects of ciprofloxacin, streptomycin and gentamicin on rabbit corneal transendothelial electrical potential difference. Cornea 1998; 17: 185–90PubMedCrossRef Kang F, Serdarevic ON, Kuang K, et al. Effects of ciprofloxacin, streptomycin and gentamicin on rabbit corneal transendothelial electrical potential difference. Cornea 1998; 17: 185–90PubMedCrossRef
61.
go back to reference Fischbarg J. Potential difference and fluid transport across rabbit corneal endothelium. Biochem Biophys Acta 1972; 228: 362–6 Fischbarg J. Potential difference and fluid transport across rabbit corneal endothelium. Biochem Biophys Acta 1972; 228: 362–6
62.
go back to reference McDermott M, Hazlett LD, Barrett R. The effects of ofloxacin on the human corneal endothelium. Cornea 1997; 16: 209–14PubMedCrossRef McDermott M, Hazlett LD, Barrett R. The effects of ofloxacin on the human corneal endothelium. Cornea 1997; 16: 209–14PubMedCrossRef
63.
go back to reference El Baba FZ, Trousdale MD, Gandermann WJ, et al. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology 1992; 99: 483–6PubMed El Baba FZ, Trousdale MD, Gandermann WJ, et al. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology 1992; 99: 483–6PubMed
64.
go back to reference Keren U, Alhalel A, Bartov E, et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci 1991; 32: 2388–92PubMed Keren U, Alhalel A, Bartov E, et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci 1991; 32: 2388–92PubMed
65.
go back to reference Alfaro DV, Hudson SJ, Rafanan MM, et al. The effect of trauma on the ocular penetration of intravenous ciprofloxacin. Am J Ophthalmol 1996; 122(5): 678–83PubMed Alfaro DV, Hudson SJ, Rafanan MM, et al. The effect of trauma on the ocular penetration of intravenous ciprofloxacin. Am J Ophthalmol 1996; 122(5): 678–83PubMed
66.
go back to reference Lesk MR, Ammann H, Marcil G, et al. The penetration of oral ciprofloxacin into the aqueous humor, vitreous and subretinal fluid of humans. Am J Ophthalmol 1993; 115: 623–8PubMed Lesk MR, Ammann H, Marcil G, et al. The penetration of oral ciprofloxacin into the aqueous humor, vitreous and subretinal fluid of humans. Am J Ophthalmol 1993; 115: 623–8PubMed
67.
go back to reference O’Brien TP, Sawusch MR, Dick JA, et al. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. Arch Ophthalmol 1988; 106: 1444–6PubMedCrossRef O’Brien TP, Sawusch MR, Dick JA, et al. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. Arch Ophthalmol 1988; 106: 1444–6PubMedCrossRef
68.
go back to reference Mochizuki K, Higashide T, Torisaki M. Effects of norfloxacin on the retina in rabbits. Graefe’s Arch Clin Exp Ophthalmol 1995; 233: 173–80CrossRef Mochizuki K, Higashide T, Torisaki M. Effects of norfloxacin on the retina in rabbits. Graefe’s Arch Clin Exp Ophthalmol 1995; 233: 173–80CrossRef
69.
go back to reference Ooishi M, Miyao M, Sakaue F, et al. Intraocular penetration of norfloxacin eye drops. Acta Med Biol 1991; 39: 67–73 Ooishi M, Miyao M, Sakaue F, et al. Intraocular penetration of norfloxacin eye drops. Acta Med Biol 1991; 39: 67–73
70.
go back to reference Ng EWM, Samiy N, Ruoff KL, et al. Treatment of experimental staphylococcus epidermidis endophtalmitis with oral trovafloxacin. Am J Ophthalmol 1998; 126(2): 278–87PubMedCrossRef Ng EWM, Samiy N, Ruoff KL, et al. Treatment of experimental staphylococcus epidermidis endophtalmitis with oral trovafloxacin. Am J Ophthalmol 1998; 126(2): 278–87PubMedCrossRef
71.
go back to reference Stern GA, Schemmer GB, Farber RD, et al. Effect of topical antibiotic solutions on corneal epithelial wound healing. Arch Ophthalmol 1983; 101: 664–7CrossRef Stern GA, Schemmer GB, Farber RD, et al. Effect of topical antibiotic solutions on corneal epithelial wound healing. Arch Ophthalmol 1983; 101: 664–7CrossRef
72.
go back to reference Davis JL. Intravenous antibiotics for endophthalmitis. Am J Ophthalmol 1996; 122(5): 724–6PubMed Davis JL. Intravenous antibiotics for endophthalmitis. Am J Ophthalmol 1996; 122(5): 724–6PubMed
73.
go back to reference Driebe Jr WT, Mandelbaum S, Forster RK. Pseudophakic endophthalmitis: diagnosis and management. Ophthalmology 1986; 93: 442–8PubMed Driebe Jr WT, Mandelbaum S, Forster RK. Pseudophakic endophthalmitis: diagnosis and management. Ophthalmology 1986; 93: 442–8PubMed
74.
go back to reference O’Day DM, Jones DB, Patrinely J, et al. Staphylococcus epidermidis endophthalmitis. Visual outcome following non-invasive therapy. Ophthalmology 1982; 89: 354–60PubMed O’Day DM, Jones DB, Patrinely J, et al. Staphylococcus epidermidis endophthalmitis. Visual outcome following non-invasive therapy. Ophthalmology 1982; 89: 354–60PubMed
75.
go back to reference Speaker MG, Milch FA, Shah MK. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98: 639–50PubMed Speaker MG, Milch FA, Shah MK. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98: 639–50PubMed
76.
go back to reference Sande MA. Antibiotic therapy of bacterial meningitis: lessons we’ve learned. Am J Med 1981; 71: 507–10PubMedCrossRef Sande MA. Antibiotic therapy of bacterial meningitis: lessons we’ve learned. Am J Med 1981; 71: 507–10PubMedCrossRef
77.
go back to reference The Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomised trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 113: 1479–96CrossRef The Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomised trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 113: 1479–96CrossRef
78.
go back to reference Grimm H. In vitro activity of new quinolones against non-fermentative gram-negative rods and interpretation of susceptibility testing. Infection 1986; 14: S191–5PubMedCrossRef Grimm H. In vitro activity of new quinolones against non-fermentative gram-negative rods and interpretation of susceptibility testing. Infection 1986; 14: S191–5PubMedCrossRef
79.
go back to reference Wise R, Andrews JM, Matthews R, et al. The in vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother 1992; 29: 649–60PubMedCrossRef Wise R, Andrews JM, Matthews R, et al. The in vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother 1992; 29: 649–60PubMedCrossRef
Metadata
Title
Fluoroquinolones
Place in Ocular Therapy
Authors
Amy Smith
Philippa M. Pennefather
Dr Stephen B. Kaye
Colin A. Hart
Publication date
01-05-2001
Publisher
Springer International Publishing
Published in
Drugs / Issue 6/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161060-00004

Other articles of this Issue 6/2001

Drugs 6/2001 Go to the issue

Adis Drug Evaluation

Perindopril

Adis New Drug Profile

Fulvestrant

Adis New Drug Profile

Zoledronic Acid